The US Food and Drug Administration has approved Hibsago, a new treatment for certain adults living with chronic hepatitis B. The decision marks a development in treatment options for a long-term viral infection that can affect liver health.
Understanding Chronic Hepatitis B
Hepatitis B is a viral infection that affects the liver. While some infections resolve, chronic hepatitis B can persist for years and may increase the risk of serious liver complications.
People living with the chronic form of the infection may need ongoing medical monitoring and treatment, depending on their condition.
Who May Be Eligible?
The new approval applies to certain adults with chronic hepatitis B, rather than every person who has the infection. Eligibility depends on the treatment’s approved criteria and the patient’s medical circumstances.
A healthcare professional can assess whether a particular treatment is suitable and explain its potential benefits, risks and monitoring requirements.
What Patients Should Know
The approval expands the treatment options available in the United States, but it does not mean that every patient should switch from an existing medicine or that the infection can necessarily be cured.
Patients should consult their treating clinicians before making changes to their medication. Availability and approval requirements may also differ between countries.
The development highlights the continuing effort to improve medical management of chronic hepatitis B and protect long-term liver health.
